IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells
By C. Klebanoff, S. Finkelstein, D. Surman, Michael K. Lichtman, L. Gattinoni, M. Theoret, N. Grewal, P. Spiess, P. Antony, D. Palmer and 4 more. Proceedings of the National Academy of Sciences of the United States of America, 2004
619 citations recorded by the source corpus.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/3369c1f61392b553752b28d494f8a5a9b82733cc
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Oncology
Citations in the corpus
- Cancer immunotherapy: the beginning of the end of cancer? (2016, background): “Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells.”
- Immunotherapy of non-Hodgkin lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells (2016, background): “Additional improvements in the cell manufacturing process might be achieved using cytokines, such as IL-7, IL-21, and/or IL-15, that have been reported to improve the growth of human T cells in vitro and enhance the therapeutic efficacy of adoptively transferred murine T cells in preclinical models ”
- Adoptive immunotherapy for cancer: harnessing the T cell response (2012, result): “, and within memory pools T CM cells show increased antitumour activity compared with T EM cells in mic”
- Interleukin 12: still a promising candidate for tumor immunotherapy? (2014, background): “The capacity of IL-15 used alone [141] or in combination with IL-21 [128] or chemotherapy [133] to further enhance efficacy of adoptive immunotherapy seems to be particularly promising.”
- Cytokines in clinical cancer immunotherapy (2018, background): “Preclinical observations strongly support the potential antitumour activity of IL-15 mediated by NK cells and T lymphocytes.(41,42) Unlike IL-2, IL-15 does not stimulate Treg cells, a subset that might reduce the anti-tumour activity of NK and T cells.”
- Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. (2005, background): “In the current article, we elucidate the T cell differentiation state (i.e., the specific phenotypic and functional qualities) of cells associated with responses in the ACT setting and clarify the Nonstandard abbreviations used: ACT, adoptive cell transfer therapy; CCR7, chemokine receptor 7; CM, cu”
- Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. (2015, background): “IL-15 demonstrated activity in syngeneic murine TRAMP (Transgenic Adenocarcinoma Mouse Prostate) C2 prostatic cancer, Pmel-1 and B16 melanoma, and MC38 and CT26 colon carcinoma models.(8,21-29) On the basis of these data, an Escherichia coli (E coli) recombinant DNA– based process was developed to p”
- CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells (2005, methodology): “As has been shown in other systems (60), the increased availability of homeostatic c-signaling cytokines such as IL-7, IL-15, or IL-21 could be enhancing T cell function in this model (24, 61, 62).”